{"ok":true,"data":{"subject":{"kind":"trial","nctId":"NCT03410875","title":"A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia","sponsor":"Memorial Sloan Kettering Cancer Center","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","indication":null,"disease":"hairy cell leukemia"},"rows":[{"n":1,"question":"Is the biology right?","flags":[{"id":"somatic_driver","label":"Somatic driver evidence","value":"yes","detail":"BRAF in hairy cell leukemia","rule":"Open Targets has somatic-mutation evidence for the target in this cancer","source":{"label":"Open Targets: BRAF in hairy cell leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0018935","date":"2026-11-11T16:14:29.599Z"},"context":[{"figure":"2.3× relative success for targets with somatic (IntOGen) support in oncology","dataset":"Minikel et al., Nature 2024","years":"drug programs to 2023","caveat":"A ratio between groups, not a probability for this program; mostly phase 2 to 3."}]},{"id":"human_genetic","label":"Human genetic evidence","value":"yes","detail":"BRAF: somatic","rule":"Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence","source":{"label":"Open Targets: BRAF in hairy cell leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0018935","date":"2026-11-11T16:14:29.599Z"},"context":[{"figure":"2.6× relative probability of success, phase 1 to launch, with human genetic support","dataset":"Minikel et al., Nature 2024","years":"drug programs to 2023","caveat":"All therapy areas, mostly germline evidence; not a probability for this program."}]},{"id":"pediatric_target","label":"Pediatric target","value":"yes","detail":"BRAF, MS4A1 on the FDA list","rule":"Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study","source":{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"},"context":[]},{"id":"haematologic","label":"Haematologic cancer","value":"yes","detail":"Haematologic","rule":"From the indication, or the registry conditions when no indication matches","source":{"label":"ClinicalTrials.gov NCT03410875","url":"https://clinicaltrials.gov/study/NCT03410875","date":"2026-11-11T16:14:29.599Z"},"context":[{"figure":"Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid","dataset":"BIO / Informa / QLS 2021","years":"2011–2020","caveat":"Population-level, not a prediction."}]}],"facts":[{"label":"BRAF (via Vemurafenib)","text":"Evidence types in hairy cell leukemia: literature, affected_pathway, somatic_mutation, clinical; literature listed separately from human genetics. Datasources: cancer_gene_census, cancer_biomarkers, clinical_precedence, europepmc.","source":{"label":"Open Targets: BRAF in hairy cell leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000157764/MONDO_0018935","date":"2026-11-11T16:14:29.599Z"}},{"label":"MS4A1 (via Obinutuzumab)","text":"Evidence types in hairy cell leukemia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: MS4A1 in hairy cell leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000156738/MONDO_0018935","date":"2026-11-11T16:14:29.599Z"}}],"pending":[{"what":"Normal-tissue expression in vital organs","source":"Human Protein Atlas (ticket 36)"},{"what":"Pan-essential in cell lines","source":"DepMap (ticket 36)"},{"what":"Approved drug on this target","source":"Drugs@FDA (ticket 30)"}]},{"n":2,"question":"Can the result be trusted?","flags":[{"id":"randomised","label":"Randomised","value":"no","detail":"Single group","rule":"Registry allocation field","source":{"label":"ClinicalTrials.gov NCT03410875","url":"https://clinicaltrials.gov/study/NCT03410875","date":"2026-11-11T16:14:29.599Z"},"context":[]},{"id":"small_denominator","label":"Small denominator","value":"no","detail":"30 enrolled; each patient moves a rate by 100 ÷ 30 = 3.3 points","rule":"Enrolment under 30; the arithmetic is shown, not a benchmark","source":{"label":"ClinicalTrials.gov NCT03410875","url":"https://clinicaltrials.gov/study/NCT03410875","date":"2026-11-11T16:14:29.599Z"},"context":[]},{"id":"primary_os","label":"Primary endpoint is overall survival","value":"no","detail":"Efficacy of vemurafenib in combination with obinutuzumab","rule":"A registered primary outcome measure names overall survival","source":{"label":"ClinicalTrials.gov NCT03410875","url":"https://clinicaltrials.gov/study/NCT03410875","date":"2026-11-11T16:14:29.599Z"},"context":[{"figure":"Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3","dataset":"Otsuka 2021, 400 phase 3 oncology trials","years":"to 2020","caveat":"Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival."},{"figure":"52% of surrogate-to-OS correlations are low","dataset":"Prasad 2015","years":"published to 2014","caveat":"Shown with the figure above."}]},{"id":"results_overdue","label":"Results overdue","value":"no","detail":"Primary completion expected 2027-01; not yet due","rule":"Primary completion (actual) more than 12 months ago and no results posted to the registry","source":{"label":"ClinicalTrials.gov NCT03410875","url":"https://clinicaltrials.gov/study/NCT03410875","date":"2026-11-11T16:14:29.599Z"},"context":[]}],"facts":[],"pending":[{"what":"Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff","source":"Readout extraction (ticket 32)"},{"what":"Primary endpoint changed between registry versions","source":"Registry versions in the store (ticket 32)"}]},{"n":3,"question":"What must it beat?","flags":[],"facts":[],"pending":[{"what":"Control-arm result and approved therapies for the same segment, with label links","source":"Drugs@FDA, FDA labels and readouts (tickets 30, 32)"}]},{"n":4,"question":"Too crowded, or too late?","flags":[],"facts":[{"label":"Stopped on this target","text":"289 terminated, withdrawn or suspended trials of drugs against BRAF; 20 of the 200 most recent give no reason. Reasons are quoted as the registry gives them on the target page.","source":{"label":"BRAF: what already stopped","url":"/target/ENSG00000157764#stopped","date":"2026-11-11T16:14:29.608Z"}}],"pending":[{"what":"Programs on the target by phase and months behind the leader","source":"Programs and Drugs@FDA (ticket 33)"}]},{"n":5,"question":"Can it be approved, and stay approved?","flags":[{"id":"single_country","label":"Single-country","value":"yes","detail":"All 9 sites in United States","rule":"All listed sites are in one country; the share of US sites is shown","source":{"label":"ClinicalTrials.gov NCT03410875","url":"https://clinicaltrials.gov/study/NCT03410875?tab=locations","date":"2026-11-11T16:14:29.599Z"},"context":[]},{"id":"eu_pip","label":"EU paediatric investigation plan","value":"yes","detail":"EMEA-001207-PIP06-22 (obinutuzumab, Prevention of cytokine release syndrome induced by anti CD20/CD3 antibodies): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), date not given; EMEA-001207-PIP05-22 (obinutuzumab, Treatment of glomerulonephritis and nephrotic syndrome): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 8 Sept 2023; EMEA-001207-PIP02-19-M01 (obinutuzumab, Treatment of Systemic Lupus Erythematosus (SLE)): PM: decision on the application for modification of an agreed PIP, 10 Aug 2022; EMEA-001207-PIP01-11-M01 (obinutuzumab, Treatment of acute lymphoblastic leukaemia;Treatment of mature B-cell lymphoma): PM: decision on the application for modification of an agreed PIP, 10 May 2021; +2 more","rule":"An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-paediatric_investigation_plans-output-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_orphan","label":"EU orphan designation","value":"yes","detail":"EU/3/15/1504 withdrawn 19 Jun 2015: Treatment of follicular lymphoma; EU/3/14/1325 withdrawn 22 Aug 2014: Treatment of diffuse large B-cell lymphoma; EU/3/12/1054 positive 10 Oct 2012: Treatment of chronic lymphocytic leukaemia; EU/3/17/1846 positive 27 Feb 2017: Treatment of Erdheim-Chester disease; +3 more","rule":"An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-orphan_designations-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_authorised","label":"Authorised in the EU","value":"yes","detail":"Gazyvaro: authorised since 22 Jul 2014; Zelboraf: authorised since 17 Feb 2012","rule":"An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"fda_orphan","label":"FDA orphan designation","value":"not published","detail":"FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link","rule":"Would be: an FDA orphan designation names the drug","source":{"label":"FDA orphan designations search","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/","date":""},"context":[]},{"id":"fda_ped_approval","label":"FDA pediatric oncology approval","value":"no","detail":"FDA's table lists no pediatric approval of Vemurafenib, Obinutuzumab","rule":"FDA's Pediatric Oncology Drug Approvals table names the drug","source":{"label":"FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03)","url":"https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals","date":"2026-11-11T16:14:29.623Z"},"context":[]},{"id":"studies_under_18","label":"Registered studies open to children","value":"yes","detail":"28 interventional studies of Vemurafenib, Obinutuzumab include patients under 18; 12 are recruiting, not yet recruiting or active","rule":"The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age","source":{"label":"ClinicalTrials.gov search","url":"https://clinicaltrials.gov/search?intr=%22Vemurafenib%22+OR+%22Obinutuzumab%22&aggFilters=ages%3Achild%2CstudyType%3Aint","date":"2026-11-11T16:14:29.627Z"},"context":[]}],"facts":[{"label":"Caveat","text":"Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality."},{"label":"Rare pediatric disease voucher","text":"FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news.","source":{"label":"FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs","url":"https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs","date":"2026-11-11"}}],"pending":[{"what":"Precedent approvals for target, modality and endpoint; accelerated-approval status","source":"Drugs@FDA and FDA accelerated-approval tables (ticket 30)"}]},{"n":6,"question":"Can the sponsor finish?","flags":[],"facts":[{"label":"Sponsor","text":"Memorial Sloan Kettering Cancer Center (academic or other)","source":{"label":"ClinicalTrials.gov NCT03410875","url":"https://clinicaltrials.gov/study/NCT03410875","date":"2026-11-11T16:14:29.599Z"}},{"label":"principal investigator","text":"Jae Park, MD, Memorial Sloan Kettering Cancer Center","source":{"label":"Person page","url":"/person/Jae%20Park%2C%20MD","date":"2026-11-11T16:14:29.599Z"}}],"pending":[{"what":"Filed cash, quarterly spend and the runway arithmetic","source":"SEC XBRL company facts (ticket 37)"},{"what":"Sponsor's completed vs stopped oncology trials and results-reporting record","source":"Registry, by company (ticket 37)"}]}],"limits":"Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.","sources":[{"label":"ClinicalTrials.gov NCT03410875","url":"https://clinicaltrials.gov/study/NCT03410875","date":"2026-11-11T16:14:29.599Z"},{"label":"Open Targets Platform","url":"https://platform.opentargets.org","date":"2026-11-11T16:14:29.599Z"},{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"}]},"source":"ClinicalTrials.gov + Open Targets","fetchedAt":"2026-11-11T16:14:29.596Z"}